Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2014 · 10-Q
Revenue$57.00K$57.00K+29.5% vs Q3 2013 Net Income-$5.38M-$5.38MN/M vs Q3 2013 EPS Diluted-$0.28-$0.28N/M vs Q3 2013 Operating Income-$3,940,228N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,510,334— Margins · derivedOperating margin-6912.7%+82.0 pt vs Q3 2013
Net margin-9430.2%+572.6 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 6, 2014 · 37 d after period end